OBJECTIVE: Evaluate the association between SARS-CoV-2 serologic status in immunologically naïve patients and risk of preeclampsia at time of delivery. STUDY DESIGN: We conducted a retrospective cohort study of pregnant patients admitted to our institution from August 1st to September 30th, 2020. We recorded maternal medical and obstetric characteristics, and SARS-CoV-2 serologic status. Our primary outcome was the incidence of preeclampsia. Antibody testing was performed and patients were classified into seropositive groups: IgG+, IgM+, or both IgG+ and IgM+. Bivariate and multivariable analyses were performed. RESULTS: We included 275 patients that were negative for SARS-CoV-2 antibodies, and 165 that were positive. Seropositivity was not associated with higher rates of preeclampsia (p=0.183), or with preeclampsia with severe features (p=0.916) even after adjusting for maternal age> 35, BMI≥ 30, nulliparity, and previous history of preeclampsia, and type of serologic status. Previous preeclampsia had the greatest association with development of preeclampsia (OR=13.40 95% CI [4.98-36.09]; p< 0.05), and with preeclampsia with severe features (OR=5.46 95% CI [1.65-18.02]; p< 0.05). CONCLUSIONS: We found that in an obstetric population there was no association between SARS-CoV-2 antibody status and the risk of preeclampsia.